Cibus Earnings Call Transcripts
Fiscal Year 2025
-
2025 marked a transformative year with major regulatory wins, expanded commercial partnerships, and significant cost reductions. The rice and sustainable ingredients programs are advancing toward key revenue milestones, supported by a strengthened cash position and streamlined operations.
-
Commercial traction accelerated with seven RISE agreements and expansion into India, targeting over $200 million in potential annual royalties. Cost reductions improved the cash runway, and initial biofragrance revenues are expected in 2026, with major commercial launches set for 2027 and beyond.
-
The conference highlighted advances in gene editing for crop productivity, rapid trait development, and a royalty-based business model targeting major crops like rice, canola, and soybean. Supportive global regulations and strong partnerships position the company for significant growth by 2027.
-
Focused execution on rice and biofragrance programs drove Q2 revenue growth and cost reductions, with initial biofragrance revenues expected in late 2025 and major rice trait launches in 2027–2028. Cash runway extends into Q2 2026, supported by a recent public offering and disciplined capital allocation.
-
Gene-edited crop traits are advancing rapidly with global regulatory acceptance, enabling a royalty-based business model targeting major crops. Key traits in rice and canola are set for commercial launch in 2027, with additional disease and herbicide tolerance traits in development.
-
Q1 2025 saw strong commercial and regulatory progress, with revenue up year-over-year and key milestones in rice, canola, and soybean platforms. Cash burn was reduced, but a $21M goodwill impairment led to a higher net loss. Regulatory advances and new partnerships support a positive outlook.
-
The conference highlighted rapid advances in industrialized gene editing for major crops, a favorable global regulatory shift, and a transition from R&D to commercial revenue with significant royalty potential. Recent fundraising, strong field trial data, and key partnerships position the business for scalable growth.
Fiscal Year 2024
-
Leadership transition and regulatory progress in the EU and California are accelerating commercialization of gene-edited traits in rice, canola, and soybean. Cost reductions improved net loss, and cash runway extends into late Q3 2025, with key milestones and initial biofragrance revenues expected in 2024–2026.
-
Transitioned to commercial-stage gene editing, achieving key milestones in rice, canola, and soybean platforms. Financials show reduced R&D and SG&A expenses, with a significant goodwill impairment impacting net loss. Commercial launches in rice and canola are on track, with strong market opportunities ahead.
-
Gene editing enables rapid, cost-effective development of crop traits for productivity, disease resistance, and sustainability, with regulatory changes opening new global markets. Royalty revenue is expected to begin in 2026, supported by major seed company partnerships and a robust trait pipeline.
-
Gene editing in agriculture is accelerating, with a royalty-based model targeting major crops and rapid global regulatory acceptance. The pipeline spans rice, canola, soybean, wheat, and corn, with significant royalty potential and partnerships driving commercialization.
-
Gene editing in agriculture is rapidly advancing, with regulatory harmonization enabling faster market entry and broad adoption. High-margin, royalty-based models are expected as major traits like herbicide tolerance and specialty ingredients reach commercialization, with significant global opportunities ahead.
-
Q2 2024 saw strong commercial and R&D progress, with expanded rice and canola platforms, new partnerships, and advanced trait development. Financials showed higher R&D costs and net loss, but cash remains solid. Soybean and Sustainable Ingredients platforms are on track for major launches.